Compare BEKE & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEKE | VTRS |
|---|---|---|
| Founded | 2001 | 1961 |
| Country | China | United States |
| Employees | N/A | 30000 |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 17.2B |
| IPO Year | 2020 | 2019 |
| Metric | BEKE | VTRS |
|---|---|---|
| Price | $15.85 | $13.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $23.70 | $13.00 |
| AVG Volume (30 Days) | 3.8M | ★ 9.6M |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | 1.71% | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $6.39 | $4.45 |
| Revenue Next Year | $9.69 | $1.79 |
| P/E Ratio | $41.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.26 | $6.85 |
| 52 Week High | $22.25 | $16.47 |
| Indicator | BEKE | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 32.97 |
| Support Level | $15.32 | $12.92 |
| Resistance Level | $17.73 | $13.49 |
| Average True Range (ATR) | 0.46 | 0.42 |
| MACD | -0.04 | -0.19 |
| Stochastic Oscillator | 4.31 | 4.82 |
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.